NDAINTRAVESICALSOLUTION
Approved
Apr 1978
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
RIMSO-50 (dimethyl sulfoxide) by Viatris (2) is pharmacology fluocinolone acetonide is chemically related to prednisolone and possesses marked anti-inflammatory properties when applied topically. First approved in 1978.
Drug data last refreshed 2d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RIMSO-50 (dimethyl sulfoxide) is an intravesical solution approved in 1978 for treating interstitial cystitis and related bladder conditions. DMSO acts as a potent penetration enhancer that reduces inflammation and edema in bladder tissue, with demonstrated anti-inflammatory activity. The drug is administered directly into the bladder where it exerts local therapeutic effects on urinary symptoms.
$0.591MPart D
LOE ApproachingDeclining
Product is in late-stage lifecycle with minimal commercial expansion; team focus shifts to maintenance and compliance rather than growth initiatives.
Mechanism of Action
PHARMACOLOGY Fluocinolone acetonide is chemically related to prednisolone and possesses marked anti-inflammatory properties when applied topically. It has been shown to have over 100 times the anti-inflammatory activity of hydrocortisone. Fluocinolone acetonide decreases edema, inflammation,…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
RIMSO-50 is a mature, niche specialty product with minimal commercial infrastructure and no identified linked career openings. Roles supporting this product exist primarily in medical affairs, regulatory compliance, and supply chain rather than growth-oriented commercial functions.
Worked on RIMSO-50 at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.